Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S.-based Alexion Pharmaceuticals has orphan designation in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder.